Jupiter Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jupiter Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-23,471	Closed	-$1.81M	–	558
2021 Q3	$1.81M	Buy	23,471 +13,598	+138%	+$1.07M	0.02%	353
2021 Q2	$824K	Buy	+9,873	New	+$783K	0.01%	454
2021 Q1	–	Sell	-5,416	Closed	-$474K	–	573
2020 Q4	$474K	Buy	+5,416	New	+$429K	﹤0.01%	513

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jupiter Asset Management's BMRN Position: Q4 2021 in Review

Jupiter Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 23,471 shares — an estimated $1.81M sold.

Jupiter Asset Management first reported a position in BMRN in Q4 2020 and held it in 3 quarters. The position peaked at $1.81M in Q3 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Jupiter Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Jupiter Asset Management sold 23,471 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $1.81M.
Jupiter Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Jupiter Asset Management's BioMarin Pharmaceuticals position peaked at $1.81M in Q3 2021.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Jupiter Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.